18F-NaF and 18F-FDG as molecular probes in the evaluation of atherosclerosis.
Mikaela L McKenney-DrakeMateen C MoghbelKoosha PaydaryMouhamad AllooshSina HoushmandSharon MoeAli SalavatiJeffrey M SturekPaul R TerritoConnie WeaverThomas J WernerPoul Flemming Høilund-CarlsenMichael SturekAbass AlaviPublished in: European journal of nuclear medicine and molecular imaging (2018)
The early detection of atherosclerotic disease is vital to the effective prevention and management of life-threatening cardiovascular events such as myocardial infarctions and cerebrovascular accidents. Given the potential for positron emission tomography (PET) to visualize atherosclerosis earlier in the disease process than anatomic imaging modalities such as computed tomography (CT), this application of PET imaging has been the focus of intense scientific inquiry. Although 18F-FDG has historically been the most widely studied PET radiotracer in this domain, there is a growing body of evidence that 18F-NaF holds significant diagnostic and prognostic value as well. In this article, we review the existing literature on the application of 18F-FDG and 18F-NaF as PET probes in atherosclerosis and present the findings of original animal and human studies that have examined how well 18F-NaF uptake correlates with vascular calcification and cardiovascular risk.
Keyphrases
- positron emission tomography
- pet ct
- pet imaging
- cardiovascular events
- cardiovascular disease
- computed tomography
- coronary artery disease
- small molecule
- single molecule
- fluorescence imaging
- endothelial cells
- systematic review
- living cells
- high resolution
- chronic kidney disease
- dual energy
- left ventricular
- magnetic resonance imaging
- type diabetes
- climate change
- photodynamic therapy
- case control
- human health
- pluripotent stem cells
- solid state